Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment.
Sho T, Suda G, Ohara M, Kohya R, Sasaki T, Yoshida S, Hosoda S, Ogawa K, Kitagataya T, Maehara O, Ohnishi S, Kawagishi N, Natsuizaka M, Nakai M, Baba M, Yamamoto Y, Tsukuda Y, Meguro T, Yamada R, Kobayashi T, Takagi T, Sakamoto N; NORTE STUDY GROUP.
Sho T, et al. Among authors: meguro t.
Target Oncol. 2024 Sep;19(5):769-778. doi: 10.1007/s11523-024-01092-7. Epub 2024 Sep 2.
Target Oncol. 2024.
PMID: 39222223